222 related articles for article (PubMed ID: 22021636)
1. Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.
Potter RM; Harikumar KG; Wu SV; Miller LJ
J Lipid Res; 2012 Jan; 53(1):137-48. PubMed ID: 22021636
[TBL] [Abstract][Full Text] [Related]
2. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
Dong M; Vattelana AM; Lam PC; Orry AJ; Abagyan R; Christopoulos A; Sexton PM; Haines DR; Miller LJ
Mol Pharmacol; 2015 Jan; 87(1):130-40. PubMed ID: 25319540
[TBL] [Abstract][Full Text] [Related]
3. Membrane cholesterol affects stimulus-activity coupling in type 1, but not type 2, CCK receptors: use of cell lines with elevated cholesterol.
Harikumar KG; Potter RM; Patil A; Echeveste V; Miller LJ
Lipids; 2013 Mar; 48(3):231-44. PubMed ID: 23306829
[TBL] [Abstract][Full Text] [Related]
4. A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.
Desai AJ; Harikumar KG; Miller LJ
J Biol Chem; 2014 Jun; 289(26):18314-26. PubMed ID: 24825903
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
Desai AJ; Lam PC; Orry A; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
J Med Chem; 2015 Dec; 58(24):9562-77. PubMed ID: 26654202
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.
Desai AJ; Dong M; Miller LJ
Clin Nutr; 2016 Dec; 35(6):1374-1379. PubMed ID: 27016394
[TBL] [Abstract][Full Text] [Related]
7. Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.
Desai AJ; Dong M; Harikumar KG; Miller LJ
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G377-86. PubMed ID: 26138469
[TBL] [Abstract][Full Text] [Related]
8. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
Dong M; Liu G; Pinon DI; Miller LJ
Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of cholesterol absorption is a mechanism for cholecystokinin-induced hypercholesterolemia.
Zhou L; Yang H; Okoro EU; Guo Z
J Biol Chem; 2014 May; 289(19):12989-99. PubMed ID: 24692543
[TBL] [Abstract][Full Text] [Related]
10. Expression of cholecystokinin receptors in colon cancer and the clinical correlation in Taiwan.
Huang BP; Lin CH; Chen YC; Kao SH
Tumour Biol; 2016 Apr; 37(4):4579-84. PubMed ID: 26508021
[TBL] [Abstract][Full Text] [Related]
11. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
Pippel M; Allison BD; Phuong VK; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2009 Nov; 19(22):6373-5. PubMed ID: 19811913
[TBL] [Abstract][Full Text] [Related]
12. Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.
Archer-Lahlou E; Tikhonova I; Escrieut C; Dufresne M; Seva C; Pradayrol L; Moroder L; Maigret B; Fourmy D
J Med Chem; 2005 Jan; 48(1):180-91. PubMed ID: 15634012
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol.
Harikumar KG; Coudrat T; Desai AJ; Dong M; Dengler DG; Furness SGB; Christopoulos A; Wootten D; Sergienko EA; Sexton PM; Miller LJ
Front Endocrinol (Lausanne); 2021; 12():789957. PubMed ID: 34950108
[TBL] [Abstract][Full Text] [Related]
14. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.
Cawston EE; Harikumar KG; Miller LJ
Am J Physiol Cell Physiol; 2012 Feb; 302(3):C615-27. PubMed ID: 22049215
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.
Harikumar KG; Cawston EE; Lam PCH; Patil A; Orry A; Henke BR; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
J Biol Chem; 2013 Jul; 288(29):21082-21095. PubMed ID: 23754289
[TBL] [Abstract][Full Text] [Related]
16. PKC-mediated inhibitory feedback of the cholecystokinin 1 receptor controls the shape of oscillatory Ca²⁺ signals.
Willems PH; Pahle J; Stalpers XL; Mugahid D; Nikolaew A; Koopman WJ; Kummer U
FEBS J; 2015 Jun; 282(11):2187-201. PubMed ID: 25779353
[TBL] [Abstract][Full Text] [Related]
17. Differential bile-pancreatic secretory effects of CCK-58 and CCK-8.
Reeve JR; Wu SV; Keire DA; Faull K; Chew P; Solomon TE; Green GM; Coskun T
Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G395-402. PubMed ID: 14604858
[TBL] [Abstract][Full Text] [Related]
18. Dual-agonist occupancy of orexin receptor 1 and cholecystokinin A receptor heterodimers decreases G-protein-dependent signaling and migration in the human colon cancer cell line HT-29.
Bai B; Chen X; Zhang R; Wang X; Jiang Y; Li D; Wang Z; Chen J
Biochim Biophys Acta Mol Cell Res; 2017 Jul; 1864(7):1153-1164. PubMed ID: 28288880
[TBL] [Abstract][Full Text] [Related]
19. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
[TBL] [Abstract][Full Text] [Related]
20. Evidence that specific interactions play a role in the cholesterol sensitivity of G protein-coupled receptors.
Geiger J; Sexton R; Al-Sahouri Z; Lee MY; Chun E; Harikumar KG; Miller LJ; Beckstein O; Liu W
Biochim Biophys Acta Biomembr; 2021 Sep; 1863(9):183557. PubMed ID: 33444621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
